Mar 25, 2019
Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress
Feb 26, 2019
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Feb 21, 2019
Theravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Feb 19, 2019
Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26
Jan 28, 2019
Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Jan 07, 2019
Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities
Dec 03, 2018
Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes
Nov 27, 2018
Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor
Nov 20, 2018
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease
Nov 19, 2018
Theravance Biopharma to Present at Two Upcoming Investor Conferences
Nov 12, 2018
Theravance Biopharma Highlights Expanded COPD Indication for Trelegy Ellipta in Europe
Nov 09, 2018
Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI(TM) (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease
Nov 06, 2018
Theravance Biopharma, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
Nov 06, 2018
Theravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland Pharmaceuticals
Oct 30, 2018
Theravance Biopharma to Report Third Quarter 2018 Financial Results on November 6
Oct 11, 2018
Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI(TM) (revefenacin) at the 2018 CHEST Annual Meeting
Oct 10, 2018
Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Oct 08, 2018
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI(TM) (revefenacin) at the 2018 CHEST Annual Meeting
Oct 08, 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2018
Oct 01, 2018
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2018